In transgenic mice with inducible TGF-β signaling, continuous bosutinib administration at 2.5–10.0 mg/kg/day for 42 days reduced skin and lung collagen accumulation. Treatment accompanied fibrosis induction; reversal of established disease was not tested. [2]
Bosutinib during induction of skin and lung fibrosis
Animal study · Male TBRIcaCol1a2-Cre mice with tamoxifen-induced constitutive TGF-β receptor I signaling; n = 6 per treatment group [2]
Bosutinib reduced induced skin and lung collagen accumulation in a dose-dependent pattern. Treatment accompanied induction; reversal of established fibrosis was not tested.
Conditions shared by the study groups
- Route
- Continuous delivery from subdermally implanted osmotic pump
- Frequency
- Continuous
- Treatment course
- 42 days, beginning following initial tamoxifen injection
- Vehicle
- Methods describe saline control pumps or bosutinib pumps; detailed drug formulation unspecified.
- 2.5 mg/kg/day bosutinib
- Model: Tamoxifen-induced male TBRIcaCol1a2-Cre mice; n = 6/group
- Reported limits: Methods enumerate four induced groups; allocation of the additional uninduced Fig. 2 control is incompletely described. Age and blinding unspecified in read methods.
- 5.0 mg/kg/day bosutinib
- Model: Tamoxifen-induced male TBRIcaCol1a2-Cre mice; n = 6/group
- Reported limits: Methods enumerate four induced groups; allocation of the additional uninduced Fig. 2 control is incompletely described. Age and blinding unspecified in read methods.
- 10.0 mg/kg/day bosutinib
- Model: Tamoxifen-induced male TBRIcaCol1a2-Cre mice; n = 6/group
- Reported limits: Methods enumerate four induced groups; allocation of the additional uninduced Fig. 2 control is incompletely described. Age and blinding unspecified in read methods.
Methods and source locations
Compound reported in the paper: Bosutinib (SKI-606); Compound label in the paper: Bosutinib
Compound-level attribution only; no salt conversion or validation of an Adooq lot.
Methods: Experimental animals; hydroxyproline determination; Statistical analyses; Fig. 2A–B/caption and associated Results
Skin and lung collagen content derived from hydroxyproline: Hydroxyproline per wet tissue converted to collagen using factor 7.5. Fig. 2: μg/mg wet tissue, n = 6/group, mean +/- standard error, performed in triplicate. General Methods instead state mean ± standard deviation; reporting inconsistency retained. — Fig. 2A–B/caption; Results: Hydroxyproline content in tissues; Methods: hydroxyproline determination and Statistical analyses
2.5 mg/kg/day bosutinib · Methods: Experimental animals; Fig. 2A–B/caption; Results: Hydroxyproline content in tissues
5.0 mg/kg/day bosutinib · Methods: Experimental animals; Fig. 2A–B/caption; Results: Hydroxyproline content in tissues
10.0 mg/kg/day bosutinib · Methods: Experimental animals; Fig. 2A–B/caption; Results: Hydroxyproline content in tissues